Affymax

Affymax, Inc. is a drug discovery powerhouse uniquely positioned to leverage over a decade of pharmaceutical drug discovery experience. As an industry pioneer with a five-year history working inside GlaxoSmithKline, one of the world’s largest pharmaceutical companies, Affymax has a proven track record of discovering promising drug leads for difficult pharmaceutical targets. Now, as an independent drug discovery company headquartered in Palo Alto, California, it is leveraging all of its rich heritage and assets to combine in one place proprietary technologies, a targeted systems-based approach, broad and deep scientific expertise and, most uniquely, a first-hand working knowledge of pharmaceutical drug development.

Contact Details: 4001 Miranda Avenue Palo Alto 94304 United States of America Tel: (650) 812-8700 Fax: (650) 424-0832 Email: info@affymax.com WWW: www.affymax.com/

Recent Publications by Affymax:
High-affinity FGFR2 binding peptides derived from the native epitope of the KGF ligand. Selection of antibodies from large repertoire phage display libraries has...	6th June, 2009	Affymax, Inc., 4001 Miranda Avenue, Palo Alto, CA 94304, USA.	Adv Exp Med Biol. 2009;611:511-2.
Discovery and optimization of a TRAIL R2 agonist for cancer therapy. Selection of antibodies from large repertoire phage display libraries has...	6th June, 2009	Affymax, Inc., 4001 Miranda Avenue, Palo Alto, CA 94304, USA.	Adv Exp Med Biol. 2009;611:101-3.
Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents. Hematide is a synthetic peptide-based, PEGylated...	2nd April, 2009	Affymax Inc,	Basic Clin Pharmacol Toxicol. 2009 Feb;104(2):155-63. Epub 2008 Dec 16. DOI Direct Link
Chronic preclinical safety evaluation of Hematide, a pegylated peptidic erythropoiesis stimulating agent in monkeys. Hematide is a synthetic peptide-based, pegylated erythropoiesis...	1st January, 2009	Affymax, Inc, 4001 Miranda Avenue, Palo Alto, CA 94304, USA.	Haematologica. 2008 Sep;93(9):1376-9. Epub 2008 Jun 2. DOI Direct Link
Designing better coumarin-based fluorogenic substrates for PTP1B. As part of a program to develop better PTP1B fluorogenic substrates that...	10th July, 2008	Affymax, Inc., Department of Chemistry, 4001 Miranda Avenue, Palo Alto, CA	Bioorg Med Chem Lett. 2008 Jun 1;18(11):3382-5. Epub 2008 Apr 13. DOI Direct Link
→View more Affymax research publications.

Press Releases on Affymax:
iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer	12th February, 2009	iZumi Bio, Inc.	MOUNTAIN VIEW, Calif., Feb. 12 /PRNewswire/ -- iZumi Bio, Inc., announced today the appointment of John P. Walker as Chief Executive Officer and a member of the company's Board of Directors.
BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism	12th January, 2009	BioTrends Research Group, Inc.	EXTON, Pa., Jan. 12 /PRNewswire/ -- BioTrends Research Group, Inc. released TreatmentTrends(TM): US Nephrology, a syndicated report based on online survey results from 305 Nephrologists in the US.
NextGen Sciences Ltd (Huntingdon, Cambridgeshire, United Kingdom) is	1st January, 1970	Nexgen	NextGen Sciences Ltd (Huntingdon, Cambridgeshire, United Kingdom) is granted a patent for producing Protein BioChips

BioNews Results for Affymax:
Affymax Announces Completion of Final Scheduled Data Monitoring Committee Review of Phase 3 ...	PipelineReview:  Nov 12 2009 12:28AM Matching: affymax
Affymax Announces Completion of Final Scheduled Data Monitoring Committee Review of Phase 3 Hematide Program	SmartBrief:  Nov 11 2009 12:45AM Matching: affymax
Affymax Announces Completion of Final Scheduled Data Monitoring Committee Review of Phase 3 Hematide Program	Pharma Live:  Nov 10 2009 9:32PM Matching: affymax
Phase 2 trail data shows Hematide increases haemoglobin & reduces blood transfusion in PRCA patients	PharmaBiz:  Nov 9 2009 4:57AM Matching: affymax
Updates for Pro-Pharmaceuticals (OTC:PRWP), Affymax (Nasdaq:AFFY), Alkermes (NASDAQ:ALKS)	Los Angeles Chronicle:  Nov 6 2009 11:49PM Matching: affymax
Promote your company here: BioNewsCast - Press Release Distribution	→View more Affymax news.

Affymax Clinical Trials:
Hematide™ Injection for Anemia in Chronic Hemodialysis (HD) Patients

Affymax Patents:
US Patent No.	Title
5733731	Peptide library and screening method
5831004	Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
5840698	Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
5861476	Peptides and compounds that bind to the IL-1 receptor
5874239	Biotinylation of proteins
→View more Affymax patents.

Affymax (AFFY) Financial information Links from Barchart
AFFY Quote from from Barchart.com
AFFY Chart from from Barchart.com
AFFY Profile from from Barchart.com
AFFY Opinion from from Barchart.com
→View more Affymax finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 29 individuals from Affymax using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 1093 times since April 2007, the link to the organisation's website has been followed 164 times

Recent Search Terms used to find this page: affymax logo | hematide patent | affymax pharma | AFFYMAX pdf | affymax | john p walker affymax | .

Search for more companies in Palo Alto

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Affymax